QBiotics receives $8.63m R&D tax incentive refund
BRISBANE, 6 June 2024.
QBiotics Group Limited (QBiotics) is delighted to report that the Company has received a research and development (R&D) tax incentive refund of $8.63m under the Australian Federal Government’s R&D Tax Incentive Scheme. The tax refund relates to eligible domestic and international R&D activities across QBiotics’ portfolio for the financial year ended 30 June 2023.
FURTHER INFORMATION
DR VICTORIA GORDON, EXECUTIVE DIRECTOR, STRATEGIC ALLIANCES & INVESTOR RELATIONS
communications@qbiotics.com
MEDIA ENQUIRIES / NOTES FOR EDITORS
JANE LOWE, IR DEPARTMENT
jane.lowe@irdepartment.com.au +61 411 117 774
ABOUT QBIOTICS
QBiotics is an unlisted public Australian life sciences company that specialises in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.
QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.
QBiotics’ lead wound healing drug candidate is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I clinical trial in patients with venous leg ulcers.